Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Naveglitazar

Home DrugsNaveglitazar

Investigational

Small Molecule

Naveglitazar

Unknown Manufacturer

Naveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Overview

Naveglitazar has been used in trials studying the treatment of Diabetes Mellitus, Non-Insulin-Dependent.

Technical identifiers

Chemical Formula: C₂₅H₂₆O₆
CAS Number: 476436-68-7
UNII ID: Y995M7GM0G

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

USE OF NAVEGLITAZAR FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF DERMATOLOGICAL CONDITIONS
WO 2007068577 A1Applicant: GALDERMA RES & DEVPriority: 2005
WO
Demethyleneberberine salt as well as preparation method, pharmaceutical composition and application thereof
CN 122187805 AApplicant: NANJING KANG CHUAN JI PHARMATECH CO LTDPriority: 2026
CN